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Context: The hypothesis that obese children are overdiagnosed with growth hormone
deficiency (GHD) has not been adequately investigated in the context of adiposity-related
differences in auxology.
Aim:To investigate the differences in auxological parameters between short, prepubertal,
obese children, and normal-weight peers who underwent growth hormone stimulation
testing (GHST).
Hypothesis: Over-weight/obese children with GHD [peak growth hormone (GH)<10µg/L]
will have higher values for growth velocity (GV) standard deviation score (SDS), bone age
minus chronological age (BA−CA), and child height SDS minus mid-parental height (MPTH)
SDS when compared to normal-weight GHD peers.
Subjects and Methods: A retrospective review of anthropometric and provocative GHST
data of 67 prepubertal, GH-naïve children of age 10.21±2.56 years (male n=45, age
10.8±2.60 years; female n=22, age 8.94±2.10). Inclusion criteria: GHST using arginine
and clonidine. Exclusion criteria: hypopituitarism, abnormal pituitary magnetic resonance
imaging scan, syndromic obesity, or syndromic short stature. Data were expressed as
mean±SD.
Results:The over-weight/obese children with peak GH of <10µg/L had significantly lower
value for natural log (ln) peak GH (1.45±0.09 vs. 1.83±0.35, p= 0.022), but similar values
for GV SDS, insulin-like growth factor-I, insulin-like growth factor binding protein-3, bone
age, BA−CA, MPTH, and child height SDS minus MPTH SDS compared to normal-weight
peers with GHD. After adjusting for covariates, the over-weight/obese children (BMI≥85th
percentile) were>7 times more likely than normal-weight subjects (BMI<85th percentile)
to have a peak GH of <10µg/L, and 23 times more likely to have a peak GH of <7µg/L
(OR=23.3, p=0.021). There was a significant inverse relationships between BMI SDS
and the ln of peak GH ( 2β=−0.40, r =0.26, p=0.001), but not for BMI SDS vs. GV SDS,
ln peak GH vs. BA, or ln peak GH vs. GV SDS.
Conclusion: Subnormal peak GH levels in obese prepubertal children are not associated
with unique pre-GHST auxological characteristics.
Keywords: growth hormone deficiency, obese children, growth hormone stimulation test, short stature, growth
velocity, bone age, mid-parental target height
INTRODUCTION
Obese children are generally taller than their non-obese peers
as demonstrated in studies carried out in the United States (1),
Australia (2), and Japan (3). These studies show that during pre-
pubertal years, obese children present with higher growth velocity
(GV) standard deviation score (SDS) and accelerated bone age
(BA) compared to non-obese children (4). However, studies that
evaluated the relationship between obesity and the diagnostic tests
for growth hormone (GH) deficiency (GHD), the GH stimulation
tests (GHST), had suggested that obese children have subnormal
peak GH response to GH secretagogues (5, 6). This has led to the
hypothesis that obese children are overdiagnosed with GHD (5–7),
which suggests a high prevalence of false-positive results in obese
children diagnosed with GHD.
However, the effect of adiposity on GV and other auxologi-
cal parameters has not been fully studied in children undergoing
GHST. Such a study may provide additional data to reduce the
rate of false-positive results from GHST, and improve the accu-
racy of the diagnosis of GHD given that the current diagnostic
gold standard for GH deficiency, the GHST, has several drawbacks
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(8). These non-physiological tests have poor reproducibility and
rely on GH assays of variable accuracy. Their results are influenced
by circulating levels of sex steroids such that some researchers
have recommended prior sex-steroid priming of prepubertal sub-
jects undergoing GHST to prevent false-positive results (9). These
tests may not discriminate between normal short children and
children with partial GHD (8). GHSTs have a high false-positive
rate, such that up to 25–67% of children diagnosed as GHD will
have a normal peak GH when retested upon the completion of
their GH therapy (10–12). As a result of the above limitations, a
careful analysis of height, GV, insulin-like growth factor-I (IGF-I),
and insulin-like growth factor binding protein-3 (IGFBP-3) and a
search for an etiology are crucial for an accurate diagnosis (13).
The current universally accepted cut-off value for the diagnosis of
GHD by GHST is a peak-stimulated GH of <10µg/L (14, 15).
Despite the limitations of the GHST, and the fact that the stud-
ies that reported diminished peak GH response in over-weight
and obese children undergoing GHST (5, 6) suggested that the
diminution in response could lead to an overdiagnosis of GHD
in these subjects (7), it is unclear whether there are auxological,
laboratory, and radiological features that could identify the over-
weight/obese children who would otherwise have a false-positive
result for GHD. For example, there is a dearth of data on the effect
of obesity on GV in children undergoing GHST.
Given the above-mentioned limitations of GHST, and the fact
that adiposity accounts for about 20% of the variability in peak
GH response (5, 7), we designed this study to investigate the rela-
tionships between the reduced GH response to secretagogues in
over-weight/obese children and their auxological, biochemical,
and radiological parameters when compared to normal-weight
individuals.
We hypothesized that over-weight/obese children with GHD
will have higher values for GV SDS, BA minus chronological age
(BA−CA),and child height SDS minus mid-parental target height
(MPTH) SDS when compared to their normal-weight GHD peers.
The study’s primary aim was to determine whether these short
obese children with peak GH of <10µg/L differed from short
normal-weight children with peak GH of <10µg/L on one hand,
and over-weight/obese children with peak GH of>10µg/L on the
other. We further examined the above relationships using a cut-off
peak GH response of<7 and<5µg/L, respectively. The secondary
aim was to determine the relationship between peak GH response
and GV SDS.
SUBJECTS AND METHODS
SUBJECTS
The study was approved by the Institutional Review Board of the
University of Massachusetts Medical School. The clinical records
of prepubertal children (n= 67; 45 males and 22 females) of mean
age 10.21± 2.56 years, were included if they had height below
the fifth percentile and had undergone two unprimed GHST
using clonidine and arginine, from 2004 to 2012. Five subjects
were excluded because they either had a one-agent GHST, or had
received other GH secretagogues such as GH releasing hormone
(GHRH). Subjects were further excluded if they had hypopitu-
itarism as diagnosed by biochemical studies showing subnormal
pituitary hormone levels; abnormal results of magnetic resonance
imaging (MRI) of the pituitary gland, history of medulloblastoma,
pituitary adenoma or any systemic illness or syndrome affecting
growth such as renal failure, or Turner syndrome, respectively.
Three subjects with peak GH of<10µg/L were excluded based on
MRI criteria.
ANTHROPOMETRY
Standing height was measured with a Harpenden stadiometer
(Holtain Ltd., Crymych, Dyfed, UK). Weight was determined
using a Detecto scale (Detecto Scale Co., Webb City, MO, USA).
Height, weight, and body mass index (BMI, weight/height2) were
expressed as SDS for age and gender based on National Center for
Health Statistics (NCHS) data (16). Gender-adjusted MPTH z-
score was calculated for 18-year-old adults using NCHS data and
the standard formula for MPTH (17). The MPTH is a child’s pro-
jected adult height based on the heights of his or her parents and
is calculated as follows: for girls, the father’s height minus 13 cm
(5′′) is averaged with the mother’s height; for boys, the mother’s
height plus 13 cm is averaged with the father’s height (17). Anthro-
pometric data were expressed as mean± SD. Heights of parents
were obtained by history (18) and 16 (23.8%) by measurement in
the clinic.
All GV data were obtained from at least two height measure-
ments of at least 12-month interval, while making certain that all
measurements occurred prior to the institution of GH therapy
in subjects who went on to receive GH treatment. GV data were
expressed as SDS based on established norms (19–21).
Pubertal status was established by pediatric endocrinologists
using the method of Tanner and Marshall (22, 23). Prepubertal
status was marked by a testicular volume of ≤3 cc in boys as mea-
sured with a Prader orchidometer, and Tanner stage 1 breasts in
girls as indicated by the absence of breast buds or breast tissue. BA
data in all patients were obtained within 6 months of GHST and
read by the same pediatric radiologist.
BIOCHEMICAL AND IMAGING STUDIES
All subjects underwent two separate GHST, without sex-steroid
priming, in a single day using clonidine (0.125 mg/m2 p.o.), and
arginine (0.5 g/kg i.v.). Samples were obtained for GH determina-
tion at times 0, 15, 30, 60, 90, and 120 min according to established
procedure (24).
ASSAYS
Serum IGFBP-3 levels were measured by radioimmunoassay (RIA)
(Esoterix, Calabasas Hills, CA, USA). Its inter-assay coefficients
of variation (CV) were 5.5, 7.8, and 18% (at 2.9, 2.7, and
1.0 mg/L), respectively. Intra-assay CV were 5.1 and 13% (at 2.7,
and 1.0 mg/L), respectively. Its sensitivity was 0.3 mg/L.
Both serum GH and IGF-I levels were measured using a solid-
phase, two-site chemiluminescent immunometric assay, Immulite
2000 (Siemens Healthcare Diagnostics, Deerfield, IL, USA). The
GH assay was referenced to the World Health Organization Second
International Standard 98/574 for somatotropin (22-kDa recom-
binant DNA-derived materials) at a standardized specific activity
of 3.0 IU/mg (25). The GH assay had an analytical sensitivity of
0.01µg/L, intra-assay CV of 2.9–4.6%, and inter-assay CV of 4.2–
6.6%; while the IGF-I assay had an analytical sensitivity of 20µg/L,
intra-assay CV of 2.3–3.9%, and inter-assay CV of 3.7–8.1%.
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Bone age was assessed using the Greulich and Pyle method
(26). BA–CA was obtained by subtracting patient’s chronological
age from his/her skeletal age.
STATISTICAL ANALYSIS
Statistical analyses were performed using the SPSS Predictive Ana-
lytics SoftWare v. 21 (IBM Corporation, Armonk, NY, USA).
Means and SD were calculated for descriptive summary statistics
and for GH, IGF-I, IGFBP-3, BA, BA–CA, and GV. Anthropomet-
ric and laboratory data were compared using Student’s t -test. The
difference in the number of male children was calculated using
Fisher’s exact test. Data were expressed as mean± SD.
Multiple linear regression models were constructed to explore
the adjusted relationship between BMI and peak GH, IGF-I,
IGFBP-3, and GV SDS. Peak GH, IGF-I, and IGFBP-3 values
were log-transformed to achieve normality. A multivariate logistic
model was fitted to the data to explore the possible relationships
between BMI and peak GH, adjusting for possible confounders.
For the analyses, subjects were first stratified by peak GH of
<10 vs.≥10µg/L;<7 vs.≥7µg/L, and then by peak GH of<5 vs.
≥5µg/L, to determine the differences in auxological parameters
between the GHD and growth hormone sufficient (GHS) subjects
using each of the above cut-off values. We evaluated the three
cut-off values because of the arbitrary nature of the choice of the
cut-off points for the diagnosis of GHD using GHST over the years.
We further analyzed the auxological, biochemical, and radiologi-
cal differences between the normal-weight and over-weight/obese
subjects stratified by peak GH levels.
In a subsequent analysis, we stratified the subjects by BMI crite-
ria to determine the differences in GV SDS and other auxological
parameters between normal-weight (BMI< 85th percentile) and
over-weight/obese subjects (BMI≥ 85th percentile).
RESULTS
Table 1 shows the patients’ characteristics stratified by BMI status.
Though the natural log (ln) of peak GH response was significantly
lower in the over-weight/obese children compared to the normal-
weight subjects (2.18± 0.82 vs. 2.83± 0.55µg/L, p= 0.011), there
were no significant differences between these groups for GV SDS
(−1.39± 1.46 vs. −1.80± 2.7, p= 0.60), BA (p= 0.31), BA–CA
(p= 0.97), MPTH (p= 0.95), and child height SDS minus MPTH
SDS (p= 0.77).
When the subjects were first stratified by a peak GH level of
10µg/L (Table 2), children with peak GH level of <10µg/L (i.e.,
GHD) were older (11.8± 2.61 vs. 9.90± 2.45 years, p= 0.042),
had higher BMI SDS (0.24± 1.03 vs. −0.50± 0.92, p= 0.044),
and significantly lower value for IGF-I SDS (−1.18± 0.74 vs.
−0.62± 0.60, p= 0.036) compared to the non-GHD children.
There were no significant differences in the values for GV SDS,
BA−CA, MPTH SDS, child height SDS minus MPTH SDS, or
IGFBP-3 between the GHD and non-GHD groups.
Similarly, when the subjects were stratified by a peak GH level
of 7µg/L, children with peak GH level of <7µg/L (i.e., GHD)
were older (12.61± 2.56 vs. 9.88± 2.40 years, p= 0.02), had
non-significantly higher BMI SDS (0.40± 1.18 vs. −0.48± 0.90,
p= 0.076) and lower IGF-I SDS (−1.26± 0.86 vs. −0.62± 0.59,
p= 0.099), but greater values for BA (11.21± 2.23 vs. 8.47± 2.54,
Table 1 | Characteristics of prepubertal patients stratified by body
mass index percentile.
Body mass index (kg/m2)
Parameter Normal weight
(BMI<85th
percentile)
Over-weight/
obese (BMI≥85th
percentile)
pValue
n=61 n=6
Age (years) 10.12± 2.52 11.17± 3.05 0.446
Height SDS −2.31± 0.67 −2.37± 0.33 0.734
Weight SDS −1.84± 0.85 −0.18± 0.49 <0.001
BMI SDS −0.54± 0.85 1.27± 0.28 <0.001
Number of males (%) 39/61 (63.9%) 6/6 (100%) 0.167
IGF-1 (µg/L) 134.37± 66.5 131.50± 40.25 0.877
IGF-I SDS 0.70± 0.64 0.82± 0.88 0.753
ln IGF-1 (µg/L) 4.77± 0.53 4.84± 0.29 0.620
IGFBP-3 (mg/L) 3.88± 1.05 4.12± 0.74 0.372
ln IGFBP-3 (mg/L) 1.32± 0.27 1.40± 0.19 0.145
Growth velocity SDS −1.8 ± 2.7 −1.39± 1.46 0.600
Bone age (BA) (years) 8.71± 2.70 9.75± 2.14 0.310
BA–CA (years) −1.40± 1.44 −1.38± 1.62 0.970
Peak GH response
(µg/L)
19.54± 12.37 11.50± 8.49 0.071
ln peak GH response
(µg/L)
2.83± 0.55 2.18± 0.82 0.011
MPTH SDS −0.51± 0.92 −0.54± 0.87 0.954
Child height
SDS – MPTH SDS
−1.83± 1.11 −1.70± 0.90 0.774
SDS, standard deviation score; IGF-I, insulin-like growth factor-I; IGFBP-3, insulin-
like growth factor binding protein-3; BA−CA, bone age minus chronological age;
MPTH, mid-parental target height. Significant p values are bolded.
p= 0.010), compared to the non-GHD children. There were no
significant differences in the values for GV SDS (−0.56± 4.49
vs. −1.94± 2.22, p= 0.453), BA−CA (p= 0.953), MPTH SDS
(p= 0.675), child height SDS minus MPTH SDS (p= 0.498), or
IGFBP-3 (p= 0.809), between the GHD and non-GHD groups.
In a subsequent analysis, patients were stratified by a peak GH
level of 5µg/L. Subjects with peak GH of <5µg/L were older
(13.83± 2.45 vs. 9.92± 2.36, p= 0.021), had non-significantly
lower values for IGF-I SDS (−1.50± 0.92 vs. −0.62± 0.59,
p= 0.99), but greater values for BMI SDS (1.04± 0.60 vs.
−0.49± 0.90, p= 0.002), and BA (12.4± 1.64 vs. 8.50± 2.50,
p= 0.003), compared to those with peak GH level of ≥5µg/L;
but similar values for GV SDS (0.06± 6.15 vs. −1.91± 2.17,
p= 0.569), BA−CA, MPTH SDS, child height SDS minus MPTH
SDS, IGF-I SDS, and IGFBP-3.
After adjusting for age and gender, the over-weight/obese chil-
dren were >7 times more likely than normal-weight subjects
to have a peak GH of <10µg/L [OR= 7.9 (95 CI 0.99–63.3)
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Table 2 | Characteristics of prepubertal subject stratified by peak
growth hormone level of 10µg/L.
Parameter Peak GH≥10 Peak GH<10 pValue
n=56 n=11
Age (years) 9.90± 2.45 11.81± 2.61 0.042
Height SDS −2.32± 0.67 −2.30± 0.51 0.918
Weight SDS −1.81± 0.89 −1.08± 1.07 0.054
BMI SDS −0.50± 0.92 0.24± 1.03 0.044
Number of males (%) 37/56 (66.1%) 8/11 (72.7%) 0.395
IGF-1 (µg/L) 137.79± 68.09 114.10± 32.15 0.094
IGF-I SDS −0.60± 0.60 −1.18± 0.74 0.036
ln IGF-1 (µg/L) 4.79± 0.54 4.70± 0.32 0.433
IGFBP-3 (mg/L) 3.92± 1.06 3.78± 0.82 0.639
ln IGFBP-3 (mg/L) 1.33± 0.27 1.31± 0.23 0.780
Growth velocity SDS −1.87± 2.17 −1.23± 4.31 0.675
Bone age (BA) (years) 8.53± 2.58 10.14± 2.70 0.093
BA−CA (years) −1.35± 1.47 −1.64± 1.37 0.542
MPTH SDS −0.53± 0.87 −0.43± 1.14 0.820
Child height
SDS – MPTH SDS
−1.79± 1.04 −2.00± 1.41 0.692
SDS, standard deviation score; IGF-I, insulin-like growth factor-I; IGFBP-3, insulin-
like growth factor binding protein-3; BA−CA, bone age minus chronological age;
MPTH, mid-parental target height. Significant p values are bolded.
p= 0.051]; and >23 times more likely to have a peak GH of
<7µg/L [OR= 23.3 (95 CI 1.61–337.1), p= 0.021].
An analysis of the characteristics of the normal-weight and
over-weight/obese subjects stratified by peak GH level of 10µg/L
showed that the over-weight/obese children with peak GH of
<10µg/L had significantly lower value for ln peak GH (1.45± 0.09
vs. 1.83± 0.35, p= 0.022), but similar values for GV SDS, IGF-
I, IGFBP-3, BA, BA−CA, MPTH, and child height SDS minus
MPTH SDS, as compared to normal-weight peers with GHD.
The analysis of the relationships between BMI SDS, ln peak
GH response, and GV SDS showed that after adjusting for age
and gender, there was a significant inverse relationship between
BMI SDS and ln peak GH level (r2= 0.26, β=−0.40, p= 0.001),
but not between BMI SDS and GV SDS (r2= 0.032, β= 0.11,
p= 0.422). There were equally no relationship between ln peak
GH and BA (r2= 0.107, β=−0.11, p= 0.654), nor between ln
peak GH and GV SDS (r2= 0.164, β=−0.061, p= 0.643) after an
initial adjustment for age and gender. However, when the above
relationship between ln peak GH and GV SDS was further adjusted
for BMI SDS, the r2 increased to 0.254 (β=−0.026, p= 0.835). A
quadratic regression analysis showed a non-significant curvilinear
relationship between BA and GV SDS (β1=−0.956, β2= 0.039;
r2= 0.0.061, p= 0.63) after adjusting for age, gender, and BMI
SDS. Further analyses showed a non-significant positive associ-
ation between BMI SDS and ln IGFBP-3 (r2= 0.12, β= 0.166,
p= 0.174); as well as BMI SDS and ln IGF-I (r2= 0.287,β= 0.123,
p= 0.257).
DISCUSSION
This study examined whether the hypothesis that short obese
children were overdiagnosed with GHD had significant corre-
lates with the GV and other auxological characteristics in these
patients when compared to short normal-weight children under-
going GHST. Its central premise was that these obese children
could demonstrate unique characteristics that differentiate them
from short, normal-weight peers. These characteristics include sig-
nificantly higher values for GV SDS, child height minus MPTH
SDS, and BA−CA. In agreement with the above hypothesis, we
found that over-weight/obese children had significantly lower peak
GH response than normal-weight children. Furthermore, children
with GHD had significantly greater BMI value than the non-GHD
subjects at peak GH cut-off values of 10 and 5µg/L, but not at
7µg/L. There were, however, no significant differences in GV SDS
between the obese and non-obese subjects, or between the sub-
jects who were diagnosed with GHD or GH sufficiency. There
were equally no differences in the values for MPTH SDS and child
height SDS minus MPTH SDS between the GHD and non-GHD
subjects; nor between the over-weight/obese and normal-weight
subjects. Subjects with GHD had significantly lower values for
IGF-I at a peak-stimulated GH cut-off value of 10µg/L, and sig-
nificantly higher values for BA at peak GH cut-off value of 5 and
7µg/L, but not at 10µg/L.
After adjusting for covariates, there was a significant inverse
relationship between BMI SDS and ln peak GH level, but no rela-
tionships between BMI SDS and GV SDS; BMI SDS and ln IGF-I;
BMI SDS and ln IGFBP-3; ln peak GH and BA; or GV SDS and BA.
Further analysis showed no differences in GV SDS, MPTH SDS,
child height SDS minus MPTH SDS, and BA−CA, between the
short, normal-weight, and the over-weight/obese subjects. The
lack of significant differences in these parameters suggests that
short obese children who were candidates for GHST had similar
auxological characteristics as their normal-weight peers.
These findings are consistent with reports from the National
Cooperative Growth Study Substudy IV showing: (1) no consistent
differences in mean height SDS, BMI SDS, and GV SDS between
patients with classic GHD and non-GHD short children; and (2)
only small or no differences in the levels of IGF-I and IGFBP-
3 between the patients selected for GH treatment and those who
were not (27). Our findings are also similar to reports of an inverse
relationship between BMI SDS and peak GH levels (5, 6), as well
as studies showing that adiposity explains about 20% of the vari-
ability in peak GH levels (5, 7). The lack of auxological distinction
between the GHD and non-GHD subjects might be due to the fact
that the GHST is an imprecise test as peak GH response is influ-
enced by several factors including nutrition (28), pubertal status
(29), genes (30), and the occurrence of endogenous GH peak just
before GHST (31).
The above finding of auxological similarity between short,
normal-weight, and over-weight/obese children undergoing
GHST differs from reports showing that obese children are gener-
ally taller than their non-obese peers (1–3). These studies report
that obese children present with higher GV SDS and accelerated BA
compared to non-obese children during the prepubertal years (4).
Subsequently, this prepubertal advantage in GV decreases during
puberty, with obese children showing a reduced growth spurt
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compared to lean subjects (32). This results in similar near adult
heights in both the obese and non-obese children (33). There were
non-significant differences in BA, or GV SDS between the over-
weight/obese children and their normal-weight peers. There was
equally no significant relationship between GV SDS and BA. The
lack of auxological distinction between the over-weight/obese chil-
dren and their normal-weight peers could also have arisen from
differences in the timing of the onset of obesity as some studies
have suggested that while early onset of obesity in the first 2 years
of life is associated with tall stature, a later onset of obesity is not
associated with tall stature (34).
The mechanism for the increased GV in childhood obesity is
unknown (35). Some reports suggest that nutrition (36), serum
concentrations of growth hormone binding protein (GHBP) (37),
leptin (38), and insulin (39) could be involved in this phenome-
non. Childhood obesity is characterized by normal or accelerated
growth in spite of abnormalities of the GH/IGF-I axis, which are
marked by reduced GH secretion with normal IGF-I levels com-
pared to normal-weight peers (32). Additionally, in concert with
leptin, increased insulin action on the IGF-I receptor has been sug-
gested as a possible mechanism for the so called growth without
GH syndrome (39).
There are a number of limitations to be considered in the
interpretation of these results. The first limitation is the cross-
sectional design of the study, which makes it impossible to establish
causality. None of our subjects received sex-steroid priming before
GHST. Even though this procedure is recommended as a tool
to prevent false-positive results during GHST, it is not widely
employed in clinical practice. The use of arginine and clonidine
as the primary GH secretagogues in our study may have increased
the proportion of false-positive cases as these agents are generally
regarded as weak secretagogues. However, clonidine and arginine
are the most widely used secretagogues in clinical practice because
the powerful secretagogues are either discontinued (e.g., GHRH,
l-DOPA) or are too dangerous to be employed in routine pediatric
clinical practice (e.g., insulin).
Another limitation is the lack of the use of an adjusted cut-off
value for the second phase of our sequential GH stimulation testing
protocol. This could, theoretically, have resulted in a high preva-
lence of false-positive results as the second test is not independent
of the first test and thus the somatotrophs may be refractory to the
effects of the second secretagogue.
Another limitation is the lack of further testing with pyridostig-
mine in our cohort of obese children with GHD. Pyridostigmine
is a cholinergic agonist that acts similar to arginine to suppress
somatostatin release by the hypothalamus. This enhances GH
response to GHRH both in normal subjects, and in many instances
of impaired GH secretion, including obesity (40). It is usually
administered in conjunction with GHRH during GH stimula-
tion testing. Some investigators recommend that the diagnosis of
GHD can only be made in an obese child in the presence of low
height velocity, low IGF-I concentrations, and a subnormal peak
GH response to standard stimulation that does not reverse with
pyridostigmine administration. This additional testing with pyri-
dostigmine is deemed necessary to prevent false-positive results
because obese individuals are believed to have impaired hypo-
thalamic secretion of GHRH, but possess a normal GH pituitary
reserve (40). However, GHRH is no longer available in the United
States, and the use of pyridostigmine is limited by its adverse effect
profile as serious cholinergic side effects ranging from transient
abdominal pain, muscle fasciculation, hypotension, and bradycar-
dia have been reported in up to 23% of patients who received
pyridostigmine during GHST (41).
We did not conduct a comprehensive biochemical evaluation
of the hypothalamic–pituitary–adrenal axis in our short obese
cohort. Such an evaluation is necessary because hypercortisolism
arising from either iatrogenic or endogenous causes, e.g., Cushing
disease, could easily lead to obesity and short stature, as a conse-
quence of the impairment of GH secretion by cortisol. Thus, ele-
vated levels of corticosteroids may inhibit or blunt GH response to
GH secretagogues resulting in false-positive results during GHST.
Our patients neither had a history of exposure to corticosteroids,
nor showed any clinical signs suggestive of Cushing’s syndrome.
Adrenal insufficiency, on the other hand, is not associated with
obesity, but could result in growth impairment. Insulin induced
hypoglycemia is employed in the simultaneous assessment of the
functional reserves of both the hypothalamic–pituitary–adrenal
axis and the GH/IGF-I axis (42). This test, however, is not rou-
tinely performed in clinical practice because of the associated risks
of hypoglycemia and death.
This study also has several strengths. We had a relatively large
sample size of prepubertal children to enable us to detect subtle
differences between the groups of interest. All subjects received
similar GH secretagogues, thus eliminating the wide variability in
peak GH response that is associated with the use of secretagogues
of differing potencies. The availability of data on GV SDS, MPTH
SDS, child height SDS minus MPTH SDS, and BA−CA enabled
us to test the hypothesis that obese children were overdiagnosed
with GHD in a novel and rigorous manner. All our results were
adjusted for possible confounders.
CONCLUSION
Though this study found evidence for reduced GH secretion dur-
ing GHST in short, prepubertal, over-weight/obese children com-
pared to their short normal-weight peers, there were no evidence
for higher GV SDS,child height minus MPTH SDS,accelerated BA,
or elevated levels of IGF-I, or IGFBP-3 in the over-weight/obese
children compared to their normal-weight peers. The absence of
adiposity-related auxological differences in short obese children
suggests that pre-GHST auxological characteristics may not be
sensitive in excluding false-positive cases of GHD.
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